Back to top
more

AbbVie (ABBV)

(Real Time Quote from BATS)

$195.33 USD

195.33
1,029,656

-2.11 (-1.07%)

Updated Aug 27, 2024 02:08 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 41% (103 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

North Chicago, IL-based AbbVie has become one of the top-most pharma companies after it acquired Botox maker Allergan in a cash-and-stock deal for $63 billion in May 2020. The deal is expected to transform AbbVie’s portfolio and lower its dependence on Humira, its flagship product, which has already lost patent protection in Europe and is due to face biosimilar competition in the United States in 2023. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest drugs Skyrizi (risankizumab) and Rinvoq (upadacitinib) position it well for long-term growth.

Ekta Bagri headshot

Biotech Sector in Focus as Coronavirus Spreads Panic

by Ekta Bagri

The outbreak of COVID-19 has brought the volatile biotech sector under the spotlight as both large and small companies rush to develop treatments and vaccines to combat this pandemic.

Gilead (GILD) Announces Positive Long-Term Results on Descovy

by Zacks Equity Research

Gilead (GILD) announces long-term results from the DISCOVER study, which showed that Descovy is effective for HIV prevention with non-inferior efficacy to Truvada.

AbbVie Backs Studies on HIV Drug Kaletra for Coronavirus Cure

by Zacks Equity Research

AbbVie (ABBV) donates Kaletra/Aluvia to the government of China for experimental use in coronavirus treatment

Bristol-Myers Empliciti Combo Fails in First-Line Myeloma Study

by Zacks Equity Research

Bristol-Myers' (BMY) Empliciti, Revlimid and dexamethasone combination regimen fails to improve progression free survival in first-line multiple myeloma patients.

The Zacks Analyst Blog Highlights: Apple, Facebook, AbbVie, Illumina and Freeport-McMoRan

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Apple, Facebook, AbbVie, Illumina and Freeport-McMoRan

Is Amgen (AMGN) Truly One of the Best Biotech Stocks to Own?

by Zacks Equity Research

Amgen (AMGN) boasts a strong biosimilars portfolio, which can drive long-term growth. Amgen is also progressing with its pipeline while regularly pursuing business development deals.

Mark Vickery headshot

Top Research Reports for Apple, Facebook & AbbVie

by Mark Vickery

Today's Research Daily features new research reports on 12 major stocks, including Apple (AAPL), Facebook (FB) and AbbVie (ABBV).

AbbVie (ABBV) Up 1.9% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

AbbVie (ABBV) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Allergan's (AGN) Glaucoma Implant Durysta Gets FDA Approval

by Zacks Equity Research

Allergan's (AGN) Durysta (bimatoprost) gets FDA approval to reduce intraocular pressure in patients with open-angle glaucoma.

Can-Fite (CANF) to Explore RA Drug for Coronavirus Treatment

by Zacks Equity Research

Can-Fite (CANF) announces plans to explore piclidenoson for the treatment of coronavirus.

Kinjel Shah headshot

Pharma Stock Roundup: Trump, Pharma Executives Meeting on Coronavirus, FDA Updates

by Kinjel Shah

Trump asks pharma firms to accelerate development of coronavirus vaccine/treatment. FDA approves Sanofi's (SNY) Sarclisa and Allergan'sa (AGN) Durysta.

The Truth About Market Timing - March 06, 2020

by Zacks Equity Research

Is the ability to time the markets more of a data-driven science or a 'gut - feeling' art?

Simple Secrets Anyone Can Use to Reach Early Retirement - March 06, 2020

by Zacks Equity Research

Accomplishing the financial cushion to retire early is a fantasy for most, but bringing that fantasy to reality is not as difficult as it sounds. If you are willing to make some serious lifestyle adjustments, it can be achievable.

AbbVie (ABBV) Stock Moves -1.21%: What You Should Know

by Zacks Equity Research

AbbVie (ABBV) closed the most recent trading day at $90.64, moving -1.21% from the previous trading session.

Alnylam, Vir Collaborate on RNAi Therapy for Coronavirus

by Zacks Equity Research

Alnylam (ALNY) expands its collaboration pact with Vir Biotechnology to develop RNAi therapeutics targeting SARS-CoV-2, the virus that induces Covid-19. Stock gains.

Inovio Surges on Expedited Timeline for Coronavirus Vaccine

by Zacks Equity Research

Inovio (INO) to initiate human clinical studies on INO-4800, its DNA vaccine, this April, for the treatment of the deadly coronavirus. The stock price shoots up.

Pfizer Plans Coronavirus Therapy, Progresses With Tanezumab BLA

by Zacks Equity Research

Pfizer (PFE) identifies potential antiviral compounds to develop a treatment for coronavirus disease. The FDA accepts regulatory application seeking approval for tanezumab for osteoarthritis.

Why You Shouldn't Bet Against AbbVie (ABBV) Stock

by Zacks Equity Research

AbbVie (ABBV) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

AbbVie's Venclexta Combo Fails in Late-Stage Leukemia Study

by Zacks Equity Research

AbbVie's (ABBV) blood cancer drug, Venclexta, in combination with chemotherapy fails to achieve statistically significant improvement in overall survival in treatment-naive AML patients.

AbbVie (ABBV) Gains As Market Dips: What You Should Know

by Zacks Equity Research

AbbVie (ABBV) closed the most recent trading day at $85.62, moving +0.23% from the previous trading session.

How Trading Your Own Retirement Can Fleece Your Financial Future - February 28, 2020

by Zacks Equity Research

From understanding your risk tolerance to maintaining emotional control, achieving your retirement goals takes a much different investing approach than regular stock trading.

Easy Investing Secrets to an Early Retirement - February 27, 2020

by Zacks Equity Research

Accomplishing the financial cushion to retire early is a fantasy for most, but bringing that fantasy to reality is not as difficult as it sounds. If you are willing to make some serious lifestyle adjustments, it can be achievable.

Zacks Value Trader Highlights: AbbVie, Allergan, Occidental, Chevron and CVS

by Zacks Equity Research

Zacks Value Trader Highlights: AbbVie, Allergan, Occidental, Chevron and CVS

Tracey Ryniec headshot

One of Your Stock Investments is Being Acquired: Now What?

by Tracey Ryniec

One of your companies gets a buyout offer and the shares soar. There might be different strategies for traders and investors on what to do next.

Signs That Your Trading Will Ruin Your Retirement - February 20, 2020

by Zacks Equity Research

Achieving your retirement goals takes a much different investing approach than regular stock trading, from smartly managing risk to keeping emotions in check.